Calliditas Therapeutics AB (publ) (0A5R.L)

111.60 +1.60 (+1.45%) As of 12:18PM BST. Market open.

Calliditas Therapeutics AB (publ)

Kungsbron 1, D5
Stockholm 111 22
Sweden
46 84 11 30 05
https://www.calliditas.se

Sector(s): 
Industry: 
Full-time employees: 217

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Renee Aguiar-Lucander	Chief Executive Officer	8.99M	N/A	1962
Mr. Fredrik Johansson	Chief Financial Officer	N/A	N/A	1977

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetes, solid tumors, and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Corporate governance

Calliditas Therapeutics AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.